MKI-2 is a selective MASTL inhibitor with an IC50 of 37.44 nM. MKI-2 induces mitotic catastrophe resulting from the modulation of the MASTL-PP2A axis in breast cancer cells. MKI-2 reduces phospho-ENSA, total, phospho-c-Myc levels. MKI-2 inhibts cancer cells proliferation, migration and induces DNA damage. MKI-2 inhibits germinal vesicle breakdown in mouse oocytes. MKI-2 can be used for the research of cancer, such as breast cancer.

METTL3-IN-11 is an excellent, selective METTL3 inhibitor (IC50 = 45.31 nM). METTL3-IN-11 exhibits high selectivity towards METTL3 compared to DNMT1, EZH1, MLL1, and PRMT1. METTL3-IN-11 reduces the m6A level of total RNA in MOLM-13 and SKOV3 cells, induces cell apoptosis, and inhibits cell migration. METTL3-IN-11 can reduce the expression of m6A downstream target genes (c-MYC and BCL2). METTL3-IN-11 can be used for the study of ovarian cancer and acute myeloid leukemia.

Methiocarb (Mercaptodimethur) is an orally active carbamate insecticide. Methiocarb exerts dose-dependent toxic effects on onions. In addition to inhibiting acetylcholinesterase to induce cholinergic excitation, Methiocarb can induce lipid peroxidation in liver, kidney, brain and testicular tissues and alter reduced glutathione levels by generating ROS. Methiocarb can be used for agricultural pest control and research on oxidative stress-related cellular damage in mammals.

Mel56 is a melanogenin analogue. Mel56 can promote the melanin production in human melanoma cells. Mel56 is cytotoxic to cancer cells and induces apoptosis in melanoma cells. Mel56 can be used for the study of melanoma.

MDL-20610 is a potent antirhinovirus compound with an median plaque 50% inhibitory concentrations (IC1/2) of 0.003 µg/mL. MDL-20610 also exhibits activity against human, simian, and bovine rotaviruses and possesses variable enterovirus and paramyxovirus activity. MDL-20610 can be used for antiviral research.

MC-Gly-Gly-Phe-Gly-PAB-MMAE (Compound SMP-81641) is a control targeted linker-agent conjugate. MC-Gly-Gly-Phe-Gly-PAB-MMAE can be used in tumor research.

Marpinersen, an antisense oligonucleotide, is an ataxin-2 synthesis reducer. It is used for the study of amyotrophic lateral sclerosis.

Mal-PEG-NHS ester (MW 2000) is a PEG linker, can be used to link lipoteichoic acid (LTA) and CpG DNA fragments to synthesis CpG-TA Heterodiners. Mal-PEG-NHS ester (MW 2000) can be used for immune stimulation research.

Lysyl-phenylalanyl-lysine (Compound KFK) is a tripeptide and belongs to the peptide segments related to thrombospondin-1 (TSP-1). Lysyl-phenylalanyl-lysine can activate LAP-TGF-β1 and release active TGF-β1, thereby inhibiting abnormal expression of MMP. Lysyl-phenylalanyl-lysine can be used for research on skin aging-related diseases and poor wound healing.

LSD1-IN-49 is a Lysine-specific demethylase 1 (LSD1/KDM1A) inhibitor with a human IC50 of 29 nM. LSD1-IN-49 irreversibly inhibits LSD1 enzyme activity by forming an adduct with the flavin adenine dinucleotide (FAD) cofactor of LSD1. LSD1-IN-49 can be used as a lead compound for the development of LSD1-targeted PET imaging agents for the brain.

LIQ1, a flavonoid derivative, is a potent Pyruvate kinase M2 (PKM2) allosteric inhibitor (IC50 = 0.39 μM; Kd = 4.5 μM) targeting Arg43 within the polyarginine pocket. LIQ1 exhibits efficacy in a mouse model of LPS-induced endotoxemia, preventing the nuclear translocation of PKM2 and inhibiting its binding to HIF-1α, thereby suppressing IL-1β transcription. LIQ1 can be used for the research of endotoxemia[1].

Lanopepden camsylate (GSK1322322 camsylate) is a high-affinity bacterial peptide deformylase inhibitor. Lanopepden camsylate is applicable to research related to bacterial infections.

L-4-Aminoarabinose-bactoprenyl phosphate (L-4-Aminoarabinose-BP) is a substrate of the ArnT enzyme and participates in lipid A modification through covalent bonding. L-4-Aminoarabinose-bactoprenyl phosphate transfers L-4-aminoarabinose (Ara4N) to the lipid A portion of lipopolysaccharide (LPS), mediating cationic modification of lipid A, thereby conferring resistance to cationic antimicrobial peptides (CAMPs) in Gram-negative bacteria. L-4-Aminoarabinose-bactoprenyl phosphate is an endogenous intermediate synthesized in vivo by a series of enzymes such as ArnC and ArnD encoded by the arn operon in Gram-negative bacteria such as Escherichia coli.

KSP-IN-2 (compound 12) is a kinesin spindle protein (KSP) inhibitor with an IC50 of 450 nM.

KSP-1007 is a bicyclic boronate-based broad-spectrum β-lactamase inhibitor. KSP-1007 can effectively inhibit class A, B, C and D β-lactamases, including serine-type, metallo-type (such as NDM, VIM, IMP) and Acinetobacter baumannii OXA-type enzymes. KSP-1007 can enhance the antibacterial activity of Meropenem, reduce its MIC value, and be effective against carbapenemase-producing Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. KSP-1007 can be used for the research of bacterial infection.

KS 501 is a potent and selective calmodulin inhibitor. KS 501 inhibits the activation of calmodulin kinase I and II, but has less effect against cyclic adenosine 3’,5’-monophosphate (cyclic AMP)-sensitive kinase. KS 501 inhibits the enzyme through interfering with calmodulin activation rather than through a direct effect on the enzyme. KS 501 can be used for the study of leukemia.

Kojic amine is an orally active γ-aminobutyric acid (GABA) analog. Kojic amine acts as a GABA mimic that inhibits sodium-independent [3H]GABA binding to rat brain cell membranes. Kojic amine reduces flexor spasms in chronic spinal rat and cat models. Kojic amine prevents tonic extensor convulsions in mice. Kojic amine produces a transient, dose-dependent analgesic effect in the mouse hot-plate test. Kojic amine can be used in research related to skeletal muscle spasm, epilepsy and analgesia[1][2]

(S)-KM-001 ((S)-KM-001) is the enantiomer of KM-001. KM-001 is a TRPV3 channel antagonist and can be used for studying skin itching and keratinosis diseases.

KIF18A-IN-19 (Compound 1) is an orally active KIF18A inhibitor with an IC50 of <0.1 μM. KIF18A-IN-19 has anti-cancer activity against ovarian cancer.

KCNT1-IN-1 (compound I-1a) is a KCNT1 inhibitor with an IC50 ≤ 250 nM. KCNT1-IN-1 can be used in the research of neurological diseases.

JNUTS013 is a NLRP3 inflammasome inhibitor. JNUTS013 promotes proteasome-dependent degradation of NLRP3 and inhibits the release of downstream cytokines. JNUTS013 downregulates the expression of inflammation-related proteins including iNOS and COX-2. JNUTS013 exhibits anti-inflammatory activity and can be used in the research of inflammatory diseases.

JAK1/2-IN-2 (Compound 37) is a potent and selective JAK1/2 inhibitor with Ki values of 2 and 0.6 nM .

Isofusidienol A (Compound 26) is a chromone compound. Isofusidienol A can be isolated from Artemisia vulgaris. Isofusidienol A has significant antibacterial activity against Bacillus subtilis. Isofusidienol A also has potent antifungal activity against Candida albicans. Isofusidienol A can be used for bacterial and fungal infections research.

IRBM-Z-2 is a non-competitive, orally active Zika virus (ZIKV) NS2B-NS3 protease inhibitor, with IC50 values of 0.04 μM and 3.1 μM against the wild-type and I156T mutant strains, respectively. IRBM-Z-2 exhibits broad-spectrum anti-flavivirus potential, with IC50 values of 2.1 μM and 0.09 μM against the NS2B-NS3 proteases of dengue virus 2 (DENV2) and West Nile virus (WNV), respectively. IRBM-Z-1 inhibits ZIKV replication and alleviates virus-induced cytopathic effects. IRBM-Z-1 can be used in studies related to ZIKV infection.

Influenza A virus-IN-17 (Compound 6a) is a potent influenza A inhibitor with EC90s of 3.5 μM and 2.6 μM for H3N2 and H1N1, respectively. Influenza A virus-IN-17 inhibits U2-PB2 chimeric mRNA (EC90 = 2.1 μM from cap snatching polymerase).

IKKβ-IN-6 is an antitumor agent. IKKβ-IN-6 inhibits IKKβ (IC50: 18.24 μM), thereby suppressing the phosphorylation of p65 and IκBα, blocking the nuclear translocation of p65, and subsequently regulating genes controlled by NF-κB. IKKβ-IN-6 also targets topoisomerase I (Topo I), induces DNA damage, ROS accumulation, loss of mitochondrial membrane potential, and S-phase arrest. IKKβ-IN-6 is applicable to related research on colorectal cancer.

Hydrouracil-(4-Br-2,6-difluorobenzene) is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. Hydrouracil-(4-Br-2,6-difluorobenzene) can be linked to a target protein ligand via a linker to form a PROTAC.

HOXA1-IN-1 is a HOXA1 inhibitor. HOXA1-IN-1 downregulates HOXA1 protein levels, suppresses its transcriptional activity, and alters the expression of its downstream target genes. HOXA1-IN-1 induces DNA damage and apoptosis in cancer cells. HOXA1-IN-1 exhibits antitumor efficacy in xenograft models of colorectal cancer and triple-negative breast cancer. HOXA1-IN-1 shows synergistic activity in combination with Cisplatin. HOXA1-IN-1 can be used for the research of colorectal cancer and triple-negative breast cancer.

HDAC1-IN-10 (Compound 2b) is a potent, selective and orally active HDAC1/2 inhibitor with IC50 values of 6 and 190 nM. HDAC1-IN-10 shows IC50 > 50 μM for HDAC3-8. HDAC1-IN-10 can inhibit tumor growth in HCT-116 colon xenograft nude mice model. HDAC1-IN-10 can be used for research of colon cancer.

HCV NS5B polymerase-IN-4 is a HCV NS5B polymerase inhibitor with an IC50 of 4.2 μM. HCV NS5B polymerase-IN-4 binds to the active site of this enzyme. HCV NS5B polymerase-IN-4 can be used in studies related to hepatitis C virus (HCV) infection.